SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia.

Nonn, O; Debnath, O; Valdes, DS; Sallinger, K; Secener, AK; Fischer, C; Tiesmeyer, S; Nimo, J; Kuenzer, T; Ulrich, J; et al. Nonn, O; Debnath, O; Valdes, DS; Sallinger, K; Secener, AK; Fischer, C; Tiesmeyer, S; Nimo, J; Kuenzer, T; Ulrich, J; Maxian, T; Knöfler, M; Karau, P; Bartolomaeus, H; Kroneis, T; Frolova, A; Neuper, L; Haase, N; Malt, A; Müller-Bötticher, N; Kräker, K; Kedziora, S; Forstner, D; Eils, R; Schmidt-Ullrich, R; Haider, S; Verlohren, S; Stern, C; Sugulle, M; Jones, S; Thilaganathan, B; Kaitu'u-Lino, TJ; Tong, S; Huppertz, B; El-Heliebi, A; Staff, AC; Coscia, F; Müller, DN; Dechend, R; Gauster, M; Ishaque, N; Herse, F (2024) Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia. Hypertension. ISSN 1524-4563 https://doi.org/10.1161/HYPERTENSIONAHA.124.23362
SGUL Authors: Thilaganathan, Baskaran

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB) | Preview
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (2MB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (40kB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (17MB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (9MB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (20kB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (24kB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (2MB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (352kB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (35kB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (145kB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (156kB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (156kB)
[img] Microsoft Excel (Supplemental Material) Supplemental Material
Download (73kB)
[img]
Preview
PDF (Supplemental Material) Supplemental Material
Download (5MB) | Preview

Abstract

BACKGROUND: Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce. METHODS: To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation. RESULTS: We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis. CONCLUSIONS: This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.

Item Type: Article
Additional Information: © 2024 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
Keywords: placenta, plasminogen activator inhibitor 1, preeclampsia, pregnancy, pregnancy trimester, first, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1117 Public Health and Health Services, Cardiovascular System & Hematology
Journal or Publication Title: Hypertension
ISSN: 1524-4563
Language: eng
Dates:
DateEvent
23 October 2024Published Online
7 October 2024Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
HE6249/5-1Deutsche Forschungsgemeinschafthttp://dx.doi.org/10.13039/501100001659
HE6249/7-1Deutsche Forschungsgemeinschafthttp://dx.doi.org/10.13039/501100001659
HE6249/7-2Deutsche Forschungsgemeinschafthttp://dx.doi.org/10.13039/501100001659
394046635-SFB 1365Deutsche Forschungsgemeinschafthttp://dx.doi.org/10.13039/501100001659
9D289VolkswagenSiftungUNSPECIFIED
BER 1.1 VDGerman Centre for Cardiovascular ResearchUNSPECIFIED
31-B26Austrian Science Fundhttp://dx.doi.org/10.13039/501100002428
PS-Stipendium 2019/2020MeFo GrazUNSPECIFIED
DGPGMGerman Association of Prenatal Diagnostics and ObstetricsUNSPECIFIED
P34588Austrian Science Fundhttp://dx.doi.org/10.13039/501100002428
P31470-B30Austrian Science Fundhttp://dx.doi.org/10.13039/501100002428
10.55776/P33554Austrian Science Fundhttp://dx.doi.org/10.13039/501100002428
10.55776/P35118Austrian Science Fundhttp://dx.doi.org/10.13039/501100002428
10.55776/DOC31Austrian Science Fundhttp://dx.doi.org/10.13039/501100002428
10.55776/I6907Austrian Science Fundhttp://dx.doi.org/10.13039/501100002428
Doc 31-B26Austrian Science Fundhttp://dx.doi.org/10.13039/501100002428
161L0222German Ministry of Education and ResearchUNSPECIFIED
031L0265German Ministry of Education and ResearchUNSPECIFIED
1159261National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
1136418National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
1065854National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
2000732National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
PubMed ID: 39440423
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/116905
Publisher's version: https://doi.org/10.1161/HYPERTENSIONAHA.124.23362

Actions (login required)

Edit Item Edit Item